Mixed
Long-term pharmacotherapy with orlistat, sibutramine, or rimonabant produces modest but statistically significant weight loss (2.9–4.7 kg) compared to placebo in adults with obesity, while improving specific cardiovascular risk factors.
Long-term use of FDA-approved anti-obesity medications (orlistat, sibutramine, rimonabant) leads to modest but real weight loss (approx. 3-5 kg more than placebo) when combined with lifestyle changes. While effective, these drugs carry specific side effect profiles (GI issues for orlistat, cardiovascular changes for sibutramine, mood disorders for rimonabant) that require monitoring and can lead to high discontinuation rates.
Compared with placebo, orlistat reduced weight by 2.9 kg (95% confidence interval 2.5 kg to 3.2 kg), sibutramine by 4.2 kg (3.6 kg to 4.7 kg), and rimonabant by 4.7 kg (4.1 kg to 5.3 kg).
Why this rating
High-quality meta-analysis of 30 randomized controlled trials, though limited by high attrition rates and pharmaceutical funding.
Source
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Diana Rucker et al. · BMJ · 2007
DOI 10.1136/bmj.39385.413113.25
More from this paper
- Orlistat improves cardiovascular risk factors, including reducing the incidence of type 2 diabetes and improving lipid profiles, despite causing gastrointestinal side effects.Good
- Sibutramine and rimonabant produce greater weight loss than orlistat but carry distinct adverse effect profiles: sibutramine increases blood pressure and heart rate, while rimonabant increases the risk of mood disorders.Good
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →